摘要
目的：探讨大剂量阿糖胞苷（HDAra—C）对急性髓细胞白血病（AML）缓解后巩固治疗的无病生存（DFS）影响。方法：以阿糖胞苷3g，静滴2～3h，q12h，连续应用6个剂量为1疗程，共用5疗程。结果：中位完全缓解期为13．5（3～167）个月，中位DFS为17．5（3～167）个月，中位总生存为22．5（7～169）个月。3年和5年的DFS率分别为54％和42％。3年和5年OS率分别为68％和49％。结论：HDAra—C用于AML的缓解后巩固治疗，可望缩短化疗时间，提高无病生存率，改善牛活质量，且患者能耐受治疗中所出现的不良反应。
Objective： To investigate the effect of high dose cytarabine （HDAra-C）on long-term disease-iree survival as postremission consolidation therapy in acute myeloid leukemia （AML）. Method： Cytarabine of 3g was intravenously infused lasted for 2～3 hrs, and once per 12 hrs for consecutive 6 dosages were considered as a course. The therapy with total 5 courses was completed in all subjects. Result： After consolidation therapy, the median duration of complete remission was 13.5 （3～167） months; the median of the disease-free survive （DFS） was 17.5（3～167） months; and overall survival （OS） was 22.5（7～169） months. The expectation of DFS at 3 and 5 years was 54% and 42% respectively. And, OS at 3 and 5 year was 68% and 49% respectively. Conclusion： The postremission consolidation chemotherapy with HDAra C can prolong DFS and improve the quality of life, and cause a few tolerated side effects.
出处
《临床血液学杂志》
CAS
2006年第5期287-288,共2页
Journal of Clinical Hematology
关键词
白血病
髓细胞性
急性
阿糖胞苷
缓解后巩固治疗
Acute myeloid leukemia
High-dose cytarabine
Postremission consolidation chemotherapy
